Myasthenia Gravis clinical trials at UC Irvine

• A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

  open to eligible people ages 18 years and up

  The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compared to placebo.

  Orange, California and other locations

• Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

  open to eligible people ages 18 years and up

  This is a Phase Ib/IIa study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis

  Irvine, California and other locations

• Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

  open to eligible people ages 18 years and up

  The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.

  Orange, California and other locations

• Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

  open to eligible people ages 18 years and up

  The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG).

  Orange, California and other locations

• Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

  open to eligible people ages 18-75

  The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.

  Orange, California and other locations

• Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

  Sorry, in progress, not accepting new patients

  The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with generalized Myasthenia Gravis (gMG). Subjects will be randomized in a 1:1:1 ratio to receive daily SC doses of 0.1 mg/kg RA101495, 0.3 mg/kg RA101495, or matching placebo for 12 weeks.

  Orange, California and other locations

Last updated: October 12, 2020